96-Hour Paclitaxel Infusions: At Least 93 Hours Too Long
作者： Bert H. O'Neil , Mark A. Socinski
关键词: Internal medicine 、 Oncology 、 Drug 、 Esophageal cancer 、 Paclitaxel 、 Medicine
摘要: Esophageal cancer remains a difficult clinical problem particularly when metastatic. When paclitaxel emerged as potentially effective esophageal drug in the early 1990s, it appeared tho...
informahealthcare.com参考文章(16)
L Gianni, C M Kearns, M J Egorin, Paclitaxel pharmacokinetics and pharmacodynamics Seminars in Oncology. ,vol. 22, pp. 16- 23 ,(1995)
A D Seidman, D Hochhauser, M Gollub, B Edelman, T J Yao, C A Hudis, P Francis, D Fennelly, T A Gilewski, M E Moynahan, V Currie, J Baselga, W Tong, M O'Donaghue, R Salvaggio, L Auguste, D Spriggs, L Norton, Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. Journal of Clinical Oncology. ,vol. 14, pp. 1877- 1884 ,(1996) , 10.1200/JCO.1996.14.6.1877
David H. Ilson, Leonard Saltz, Peter Enzinger, Ying Huang, Alice Kornblith, Marc Gollub, Eileen O'Reilly, Gary Schwartz, Julia DeGroff, Gladys Gonzalez, David P. Kelsen, Phase II Trial of Weekly Irinotecan Plus Cisplatin in Advanced Esophageal Cancer Journal of Clinical Oncology. ,vol. 17, pp. 3270- 3275 ,(1999) , 10.1200/JCO.1999.17.10.3270
Mark A Socinski, Paul N Mudd, Kristine M Radomski, Ann Steagall, Pam Lawrence, Stephen Bernard, Stephen P Letrent, Pablo Gonzalez, Kim LR Brouwer, Phase I trial of a 96 h paclitaxel infusion with filgrastim support in refractory solid tumor patients. Anti-Cancer Drugs. ,vol. 9, pp. 611- 619 ,(1998) , 10.1097/00001813-199808000-00006
Mark A. Socinski, Michael J. Schell, Kamal Bakri, Amy Peterman, Ji-Hyun Lee, Paul Unger, Steven Yates, Stacie Hudgens, Merrill S. Kies, Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel. Cancer. ,vol. 95, pp. 1265- 1273 ,(2002) , 10.1002/CNCR.10835
Maurie Markman, James Hall, Daniel Spitz, Sheldon Weiner, Linda Carson, Linda Van Le, Mark Baker, Phase II Trial of Weekly Single-Agent Paclitaxel in Platinum/Paclitaxel-Refractory Ovarian Cancer Journal of Clinical Oncology. ,vol. 20, pp. 2365- 2369 ,(2002) , 10.1200/JCO.2002.09.130
S Petrasch, A Welt, A Reinacher, U Graeven, M König, W Schmiegel, Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. British Journal of Cancer. ,vol. 78, pp. 511- 514 ,(1998) , 10.1038/BJC.1998.524
Jacob J. Lokich, Henry Sonneborn, Norwood R. Anderson, Murray M. Bern, Frank V. Coco, Edward Dow, Peter Oliynyk, Combined paclitaxel, cisplatin, and etoposide for patients with previously untreated esophageal and gastroesophageal carcinomas. Cancer. ,vol. 85, pp. 2347- 2351 ,(1999) , 10.1002/(SICI)1097-0142(19990601)85:11<2347::AID-CNCR8>3.0.CO;2-8
Sibyl E. Anderson, Eileen M. O'Reilly, David P. Kelsen, David H. Ilson, Phase II trial of 96-hour paclitaxel in previously treated patients with advanced esophageal cancer. Cancer Investigation. ,vol. 21, pp. 512- 516 ,(2003) , 10.1081/CNV-120022360
Mark A. Socinski, Ann Steagall, Heidi Gillenwater, Second-line chemotherapy with 96-hour infusional paclitaxel in refractory non-small cell lung cancer: report of a phase II trial. Cancer Investigation. ,vol. 17, pp. 181- 188 ,(1999) , 10.3109/07357909909021419